Jimscaline

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Jimscaline
Jimscaline.png
Systematic (IUPAC) name
(R)-(2,3-dihydro-4,5,6-trimethoxy-1H-inden-1-yl)aminomethane
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Number 890309-57-6 N
ATC code none
PubChem CID: 11673493
ChemSpider 9848222 N
Chemical data
Formula C13H19NO3
Molecular mass 237.294 g/mol
  • COC1=C(C(=C2CC[C@H](C2=C1)CN)OC)OC
  • InChI=1S/C13H19NO3/c1-15-11-6-10-8(7-14)4-5-9(10)12(16-2)13(11)17-3/h6,8H,4-5,7,14H2,1-3H3/t8-/m0/s1 N
  • Key:AFTIZGHFDCOQFS-QMMMGPOBSA-N N
 NYesY (what is this?)  (verify)

Jimscaline (C-(4,5,6-trimethoxyindan-1-yl)methanamine) is a conformationally-restricted derivative of the cactus-derived hallucinogen mescaline, which was discovered in 2006 by a team at Purdue University led by David E. Nichols. It acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with the more active (R)-enantiomer having a Ki of 69 nM at the human 5-HT2A receptor, and around three times the potency of mescaline in drug-substitution experiments in animals.[1] This discovery that the side chain of the phenethylamine hallucinogens could be constrained to give chiral ligands with increased activity then led to the later development of the super-potent benzocyclobutene derivative TCB-2.[2][3]

See also

References

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.

<templatestyles src="Asbox/styles.css"></templatestyles>